Immunovant Historical Balance Sheet

IMVT Stock

USD 25.39 0.19 0.75%

Trend analysis of Immunovant balance sheet accounts such as Total Stockholder Equity of 648.6 M or Net Tangible Assets of 242.7 M provides information on Immunovant's total assets, liabilities, and equity, which is the actual value of Immunovant to its prevalent stockholders. By breaking down trends over time using Immunovant balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Immunovant latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunovant is a good buy for the upcoming year.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.

About Immunovant Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Immunovant at a specified time, usually calculated after every quarter, six months, or one year. Immunovant Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Immunovant and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Immunovant currently owns. An asset can also be divided into two categories, current and non-current.

Immunovant Balance Sheet Chart

At this time, Immunovant's Total Assets are comparatively stable compared to the past year. Total Stockholder Equity is likely to gain to about 648.6 M in 2024, whereas Accounts Payable is likely to drop slightly above 5 M in 2024.

Total Assets Total Current Liabilities Accounts Payable Common Stock Shares Outstanding Short Long Term Debt Total

Add Fundamental

Total Assets

Total assets refers to the total amount of Immunovant assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Immunovant books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Immunovant balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Immunovant are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Immunovant obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Immunovant are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most accounts from Immunovant's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Immunovant current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunovant. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.At this time, Immunovant's Total Assets are comparatively stable compared to the past year. Total Stockholder Equity is likely to gain to about 648.6 M in 2024, whereas Accounts Payable is likely to drop slightly above 5 M in 2024.

	2021	2022	2023	2024 (projected)
Total Current Liabilities	44.5M	43.3M	48.6M	27.1M
Total Assets	515.6M	405.8M	666.4M	699.7M

Total Current Liabilities Total Assets

Immunovant balance sheet Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Accounts Payable	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Other Current Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Deferred Long Term Liab	Net Invested Capital
Total Assets		0.9	1.0	0.91	0.63	0.92	0.99	0.91	1.0	0.67	0.95	0.62	-0.85	-0.93	-0.95	0.96	0.6	0.83	0.93	0.4	0.93	-0.05	0.92	0.81	-0.89	0.96
Total Current Liabilities	0.9		0.9	0.94	0.69	0.98	0.94	1.0	0.9	0.59	0.91	0.61	-0.87	-0.92	-0.88	0.95	0.59	0.9	0.94	0.47	0.98	0.04	0.98	0.88	-0.88	0.95
Total Stockholder Equity	1.0	0.9		0.9	0.62	0.92	0.98	0.9	1.0	0.67	0.94	0.62	-0.84	-0.93	-0.95	0.96	0.6	0.82	0.93	0.4	0.93	-0.06	0.92	0.8	-0.88	0.96
Net Tangible Assets	0.91	0.94	0.9		0.7	0.96	0.91	0.95	0.91	0.71	0.82	0.83	-0.9	-0.98	-0.79	0.97	0.82	0.91	1.0	0.42	0.97	0.01	0.97	0.79	-0.9	0.97
Accounts Payable	0.63	0.69	0.62	0.7		0.61	0.59	0.69	0.63	0.43	0.47	0.56	-0.53	-0.7	-0.48	0.68	0.55	0.54	0.71	0.94	0.61	-0.06	0.62	0.28	-0.53	0.67
Common Stock Shares Outstanding	0.92	0.98	0.92	0.96	0.61		0.95	0.98	0.92	0.63	0.91	0.67	-0.89	-0.93	-0.89	0.98	0.66	0.92	0.96	0.34	1.0	0.02	1.0	0.91	-0.9	0.98
Other Stockholder Equity	0.99	0.94	0.98	0.91	0.59	0.95		0.94	0.99	0.63	0.98	0.6	-0.86	-0.93	-0.97	0.95	0.58	0.84	0.93	0.36	0.95	-0.06	0.95	0.88	-0.89	0.95
Total Liab	0.91	1.0	0.9	0.95	0.69	0.98	0.94		0.91	0.61	0.9	0.63	-0.88	-0.93	-0.88	0.96	0.62	0.91	0.95	0.47	0.98	0.04	0.99	0.88	-0.89	0.96
Total Current Assets	1.0	0.9	1.0	0.91	0.63	0.92	0.99	0.91		0.67	0.95	0.61	-0.85	-0.93	-0.95	0.96	0.59	0.83	0.93	0.4	0.93	-0.05	0.92	0.81	-0.89	0.96
Short Long Term Debt Total	0.67	0.59	0.67	0.71	0.43	0.63	0.63	0.61	0.67		0.57	0.71	-0.89	-0.75	-0.48	0.66	0.73	0.84	0.72	0.21	0.69	0.59	0.6	0.44	-0.88	0.66
Other Current Liab	0.95	0.91	0.94	0.82	0.47	0.91	0.98	0.9	0.95	0.57		0.43	-0.83	-0.84	-0.99	0.89	0.41	0.81	0.84	0.27	0.91	0.01	0.9	0.91	-0.87	0.89
Property Plant And Equipment Net	0.62	0.61	0.62	0.83	0.56	0.67	0.6	0.63	0.61	0.71	0.43		-0.71	-0.83	-0.38	0.71	1.0	0.68	0.82	0.26	0.7	0.0	0.68	0.42	-0.68	0.71
Current Deferred Revenue	-0.85	-0.87	-0.84	-0.9	-0.53	-0.89	-0.86	-0.88	-0.85	-0.89	-0.83	-0.71		0.91	0.75	-0.87	-0.72	-0.98	-0.9	-0.28	-0.92	-0.4	-0.87	-0.77	1.0	-0.87
Net Debt	-0.93	-0.92	-0.93	-0.98	-0.7	-0.93	-0.93	-0.93	-0.93	-0.75	-0.84	-0.83	0.91		0.81	-0.95	-0.82	-0.88	-0.99	-0.43	-0.95	-0.01	-0.94	-0.76	0.91	-0.95
Retained Earnings	-0.95	-0.88	-0.95	-0.79	-0.48	-0.89	-0.97	-0.88	-0.95	-0.48	-0.99	-0.38	0.75	0.81		-0.89	-0.36	-0.75	-0.82	-0.29	-0.88	0.11	-0.89	-0.9	0.8	-0.89
Cash	0.96	0.95	0.96	0.97	0.68	0.98	0.95	0.96	0.96	0.66	0.89	0.71	-0.87	-0.95	-0.89		0.69	0.9	0.98	0.42	0.98	-0.03	0.98	0.84	-0.89	1.0
Non Current Assets Total	0.6	0.59	0.6	0.82	0.55	0.66	0.58	0.62	0.59	0.73	0.41	1.0	-0.72	-0.82	-0.36	0.69		0.69	0.8	0.26	0.69	0.04	0.66	0.4	-0.68	0.69
Non Currrent Assets Other	0.83	0.9	0.82	0.91	0.54	0.92	0.84	0.91	0.83	0.84	0.81	0.68	-0.98	-0.88	-0.75	0.9	0.69		0.91	0.29	0.94	0.38	0.9	0.8	-0.97	0.9
Cash And Short Term Investments	0.93	0.94	0.93	1.0	0.71	0.96	0.93	0.95	0.93	0.72	0.84	0.82	-0.9	-0.99	-0.82	0.98	0.8	0.91		0.43	0.98	0.01	0.97	0.79	-0.91	0.98
Net Receivables	0.4	0.47	0.4	0.42	0.94	0.34	0.36	0.47	0.4	0.21	0.27	0.26	-0.28	-0.43	-0.29	0.42	0.26	0.29	0.43		0.34	-0.04	0.36	0.04	-0.29	0.41
Common Stock Total Equity	0.93	0.98	0.93	0.97	0.61	1.0	0.95	0.98	0.93	0.69	0.91	0.7	-0.92	-0.95	-0.88	0.98	0.69	0.94	0.98	0.34		0.07	0.99	0.89	-0.93	0.98
Non Current Liabilities Total	-0.05	0.04	-0.06	0.01	-0.06	0.02	-0.06	0.04	-0.05	0.59	0.01	0.0	-0.4	-0.01	0.11	-0.03	0.04	0.38	0.01	-0.04	0.07		-0.03	-0.02	-0.37	-0.03
Capital Surpluse	0.92	0.98	0.92	0.97	0.62	1.0	0.95	0.99	0.92	0.6	0.9	0.68	-0.87	-0.94	-0.89	0.98	0.66	0.9	0.97	0.36	0.99	-0.03		0.91	-0.88	0.98
Other Current Assets	0.81	0.88	0.8	0.79	0.28	0.91	0.88	0.88	0.81	0.44	0.91	0.42	-0.77	-0.76	-0.9	0.84	0.4	0.8	0.79	0.04	0.89	-0.02	0.91		-0.79	0.84
Deferred Long Term Liab	-0.89	-0.88	-0.88	-0.9	-0.53	-0.9	-0.89	-0.89	-0.89	-0.88	-0.87	-0.68	1.0	0.91	0.8	-0.89	-0.68	-0.97	-0.91	-0.29	-0.93	-0.37	-0.88	-0.79		-0.89
Net Invested Capital	0.96	0.95	0.96	0.97	0.67	0.98	0.95	0.96	0.96	0.66	0.89	0.71	-0.87	-0.95	-0.89	1.0	0.69	0.9	0.98	0.41	0.98	-0.03	0.98	0.84	-0.89

Click cells to compare fundamentals

Immunovant Account Relationship Matchups

Immunovant balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	109.4M	412.5M	515.6M	405.8M	666.4M	699.7M
Total Current Liabilities	15.3M	18.8M	44.5M	43.3M	48.6M	27.1M
Total Stockholder Equity	94.1M	391.5M	469.8M	362.5M	617.8M	648.6M
Net Tangible Assets	94.1M	391.5M	469.8M	362.5M	416.9M	242.7M
Accounts Payable	1.2M	2.4M	18.6M	1.4M	7.2M	5.0M
Common Stock Shares Outstanding	43.2M	87.8M	109.7M	123.1M	145.6M	82.0M
Other Stockholder Equity	185.3M	590.4M	824.8M	928.0M	1.1B	1.1B
Total Liab	15.3M	21.0M	45.7M	43.3M	48.6M	27.7M
Total Current Assets	109.1M	409.0M	512.9M	404.3M	665.8M	699.1M
Short Long Term Debt Total	3.2M	3.4M	2.4M	1.2M	1.4M	2.3M
Other Current Liab	14.1M	15.2M	24.7M	40.8M	46.9M	49.2M
Property Plant And Equipment Net	65K	3.5M	2.6M	1.5M	595K	565.3K
Net Debt	(97.4M)	(396.7M)	(491.5M)	(375.3M)	(337.8M)	(354.7M)
Retained Earnings	(91.2M)	(198.7M)	(355.4M)	(566.3M)	(825.7M)	(784.4M)
Cash	100.6M	400.1M	493.8M	376.5M	635.4M	367.9M
Non Current Assets Total	311K	3.5M	2.6M	1.5M	595K	565.3K
Cash And Short Term Investments	100.6M	400.1M	493.8M	376.5M	433.0M	301.7M
Net Receivables	3.0M	548K	12.9M	885K	5.3M	4.7M
Common Stock Total Equity	5K	10K	12K	13K	15.0K	8.9K
Liabilities And Stockholders Equity	109.4M	412.5M	515.6M	405.8M	466.7M	317.6M
Capital Surpluse	185.3M	590.4M	824.8M	928.0M	1.1B	556.3M
Other Current Assets	5.5M	8.3M	6.3M	26.9M	24.9M	13.2M
Net Invested Capital	94.1M	391.5M	469.8M	362.5M	617.8M	354.9M
Capital Stock	5K	10K	12K	13K	14K	10.0K
Net Working Capital	93.8M	390.2M	468.4M	361.0M	617.2M	353.9M
Short Term Debt	3.2M	1.2M	1.1M	1.2M	1.1M	1.1M
Common Stock	5K	10K	12K	13K	15.0K	8.9K
Property Plant Equipment	65K	201K	330K	333K	383.0K	216.3K

Pair Trading with Immunovant

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunovant position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunovant will appreciate offsetting losses from the drop in the long position's value.

Moving together with Immunovant Stock

0.63

ETON

Eton Pharmaceuticals

Pair Corr

Moving against Immunovant Stock

0.54	VRCA	Verrica Pharmaceuticals	Pair Corr
0.46	DSGN	Design Therapeutics	Pair Corr
0.44	ELDN	Eledon Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to Immunovant could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunovant when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunovant - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunovant to buy it.

The correlation of Immunovant is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunovant moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunovant moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Immunovant can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immunovant Historical Balance Sheet

About Immunovant Balance Sheet Analysis

Immunovant Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Common Stock Shares Outstanding

Immunovant balance sheet Correlations

Immunovant Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunovant balance sheet Accounts

Pair Trading with Immunovant

Moving together with Immunovant Stock

Moving against Immunovant Stock

Additional Tools for Immunovant Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Net Tangible Assets
Common Stock Total Equity	+ 1.0	Common Stock Shares Outstanding

Cash And Short Term Investments	- 0.99	Net Debt
Retained Earnings	- 0.99	Other Current Liab
Non Currrent Assets Other	- 0.98	Current Deferred Revenue
Net Debt	- 0.98	Net Tangible Assets
Deferred Long Term Liab	- 0.97	Non Currrent Assets Other
Retained Earnings	- 0.97	Other Stockholder Equity